Provaris Energy Ltd (ASX:PV1, OTC:GBBLF, FRA:WS90) has completed a $1 million placement to support key 2026 technical ...
The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip ...
Recent Clinical Progress, Enrollment Achievements, Expanded Intellectual Property Portfolio and Strengthened Financial Position Support a Potentially Transformative 12-Month Value Creation Opportunity ...
LLVM powers the core development tools, operating systems, and most applications at Apple Computer, where it long ago ...
St. Louis will host July workshops and a virtual meeting to present draft zoning development standards, share map updates, ...
Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 305, ...
PARP inhibitors reshaped oncology when they first reached patients some 10 years ago, but they represent just one entry point into a much larger and more intricate biological network.
A new generation of reversible male contraceptives is advancing through clinical trials to expand family planning options.
The new agreement creates more competition but could leave officials "looking over their shoulders." ...
(Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without active liver metastases (non-liver metastases, ...
LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results